I

    IRIDEX Corporation (IRIX)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NASDAQ

    $0.72
    +0.02 (+2.42%)

    Market Cap: $12.60M

    Last updated: Sep 01, 2026 at 5:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    60%(24/40)
    Avg Surprise
    -41.14%

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.04
    Range$-0.04 - $-0.04
    1 analysts
    EPS Revisions
    1
    0
    7d
    1
    0
    30d
    EPS Estimate Drift
    90d ago$-0.02+50.0%
    60d ago$-0.02+50.0%
    30d ago$-0.02+50.0%
    7d ago$-0.02+50.0%
    Current$-0.04
    Revenue Consensus
    $13M
    Range$13M - $13M
    1 analysts
    Period ending Dec 31, 2026
    EPS Consensus$0.00
    Range$0.00 - $0.00
    1 analysts
    Revenue Consensus
    $14M
    Range$14M - $14M
    1 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$0.00---
    Sep 26EST
    		-$-0.04---
    Jun 26
    Reported Aug 18
    		$-0.07$-0.01-600.00%Miss-16.7%
    Mar 26
    Reported May 19
    		$-0.03N/A+57.14%Beat+70.2%
    Dec 25
    Reported Mar 26
    		$-0.01$-0.02+46.50%Beat+78.6%
    Sep 25
    Reported Nov 11
    		$-0.09$-0.06-50.00%Miss+25.0%
    Jun 25
    Reported Aug 12
    		$-0.06$-0.09+33.33%Beat+62.5%
    Mar 25
    Reported May 13
    		$-0.10$-0.12+16.00%Beat+52.0%
    Dec 24
    Reported Mar 27
    		$-0.05$-0.05-0.20%Miss+72.2%
    Sep 24
    Reported Nov 12
    		$-0.12$-0.09-33.33%Miss-9.1%
    Jun 24
    Reported Aug 8
    		$-0.16$-0.12-33.33%Miss+5.9%
    Mar 24
    Reported May 14
    		$-0.21$-0.12-75.00%Miss-61.5%
    Dec 23
    Reported Mar 26
    		$-0.18$-0.05-260.00%Miss-157.1%
    Sep 23
    Reported Nov 14
    		$-0.11$-0.12+8.33%Beat+0.0%
    Jun 23
    Reported Aug 10
    		$-0.17$-0.11-54.55%Miss-21.4%
    Mar 23
    Reported May 11
    		$-0.13$-0.12-8.33%Miss+13.3%
    Dec 22
    Reported Mar 9
    		$-0.07$-0.11+36.36%Beat+53.3%
    Sep 22
    Reported Nov 10
    		$-0.11$-0.14+21.43%Beat+21.4%
    Jun 22
    Reported Aug 15
    		$-0.14$-0.15+6.67%Beat-255.6%
    Mar 22
    Reported May 12
    		$-0.15$-0.16+6.25%Beat-7.1%
    Dec 21
    Reported Mar 10
    		$-0.15$-0.11-36.36%Miss-1400.0%
    Sep 21
    Reported Nov 11
    		$-0.14$-0.14+0.00%Beat-16.7%
    Jun 21
    Reported Aug 12
    		$0.09$-0.15+160.00%Beat+145.0%
    Mar 21
    Reported May 11
    		$-0.14$-0.14+0.00%Beat-16.7%
    Dec 20
    Reported Mar 22
    		$-0.01N/A+90.00%Beat+90.9%
    Sep 20
    Reported Nov 9
    		$-0.12$-0.17+29.41%Beat+7.7%
    Jun 20
    Reported Aug 6
    		$-0.20$-0.22+9.09%Beat-11.1%
    Mar 20
    Reported May 11
    		$-0.12$-0.19+36.84%Beat+45.5%
    Dec 19
    Reported Mar 12
    		$-0.11$-0.15+26.67%Beat+47.6%
    Sep 19
    Reported Nov 7
    		$-0.13$-0.19+31.58%Beat+50.0%
    Jun 19
    Reported Aug 6
    		$-0.18$-0.22+18.18%Beat+35.7%
    Mar 19
    Reported May 2
    		$-0.22$-0.24+8.33%Beat+29.0%
    Dec 18
    Reported Mar 5
    		$-0.21$-0.24+12.50%Beat+52.3%
    Sep 18
    Reported Nov 1
    		$-0.26$-0.28+7.14%Beat+7.1%
    Jun 18
    Reported Aug 2
    		$-0.28$-0.32+12.50%Beat-16.7%
    Mar 18
    Reported May 3
    		$-0.31$-0.33+6.06%Beat-93.8%
    Dec 17
    Reported Mar 8
    		$-0.44$-0.27-62.96%Miss+57.3%
    Sep 17
    Reported Nov 2
    		$-0.28$-0.15-86.67%Miss-300.0%
    Jun 17
    Reported Aug 3
    		$-0.24$-0.12-100.00%Miss-
    Mar 17
    Reported May 3
    		$-0.16$-0.12-33.33%Miss-
    Dec 16
    Reported Mar 8
    		$-1.03$-0.12-758.33%Miss-
    Sep 16
    Reported Nov 3
    		$-0.07$-0.03-133.33%Miss-

    Key Metrics

    Valuation
    P/E Ratio-3.61EV/EBITDA-3.61x
    Price/FCF-6.13xFCF Yield-16.31%
    Profitability
    Profit Margin-6.88%Operating Margin-8.19%
    ROE-73.20%ROIC-37.54%
    Financial Health
    Debt/Equity0.04xInterest Coverage-2.30x
    Current Ratio1.82xQuick Ratio1.08x
    Trading Statistics
    Beta0.64Avg Volume105.52K
    52-Week High$1.6552-Week Low$0.70

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$0.75
    SMA 20$0.80
    SMA 50$0.94
    SMA 200$1.11
    EMA 10$0.75
    EMA 20$0.79
    EMA 50$0.89
    EMA 200$1.06

    MACD

    Line: -0.06Signal: -0.06Hist: -0.00

    ADX

    ADX: 38.6+DI: 14.3-DI: 32.6

    Aroon & PSAR

    Aroon Up64.0
    Aroon Down88.0
    PSAR$0.92

    Bollinger Bands

    Upper Band$0.94
    Lower Band$0.66
    %B Position3446%(Upper)
    Band Width0.22

    RSI (14-Day)

    Neutral
    33.7

    Momentum Oscillators

    Stoch %K5.6
    Stoch %D4.6
    Williams %R-91.0
    ROC (10d)-17.8%
    Momentum-0.16
    CCI (20d)-91.6
    MFI (14d)34.5

    Volatility Measures

    ATR (14d)$0.05(6.9%)
    StdDev (20d)0.07
    Hist Vol73.8%(High)

    Volume Flow

    VWAP$0.72
    OBV7.4M
    AD Line-7.6M
    CMF (20d)-0.156

    Volume Metrics

    Avg Vol (20d)104.9K
    Vol Ratio0.3x(Low)
    VWMA (20d)$0.80

    Pivot Points

    R3$0.74
    R2$0.73
    R1$0.72
    Pivot Point$0.71
    S1$0.70
    S2$0.69
    S3$0.68

    Advanced Oscillators

    TSI-34.47
    Ultimate Osc34.3
    KST-179.46

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$12.57M$11.80M$14.72M$12.48M$13.57M$11.90M$12.70M$11.58M$12.63M$11.76M$12.46M$12.85M
    Cost of Revenue$8.27M$7.06M$9.09M$8.47M$8.97M$6.84M$7.11M$7.26M$7.50M$7.39M$7.66M$7.23M
    Gross Profit$4.30M$4.74M$5.63M$4.01M$4.60M$5.05M$5.59M$4.32M$5.13M$4.37M$4.80M$5.62M
    Operating Expenses$5.33M$5.07M$5.65M$5.42M$5.54M$5.26M$6.09M$6.19M$7.77M$7.67M$7.88M$7.31M
    R&D$936,000$905,000$949,000$972,000$871,000$876,000$1.11M$1.30M$1.50M$1.54M$1.69M$1.54M
    SG&A$1.84M$1.62M$1.79M$1.79M$2.22M$1.93M$2.27M$2.25M$2.79M$2.47M$2.40M$1.95M
    Operating Income$-1,029,000$-324,000$-15,000$-1,411,000$-940,000$-205,000$-502,000$-1,870,000$-2,638,000$-3,293,000$-3,081,000$-1,688,000
    Interest Income$0$0$0$0$0$0$0$0$0$0$0$0
    Interest Expense$167,000$142,000$149,000$158,000$33,000$1.47M$338,000$46,000$22,000$133,000$0$58,000
    Income Before Tax$-1,196,000$-466,000$-164,000$-1,569,000$-973,000$-1,674,000$-840,000$-1,916,000$-2,660,000$-3,426,000$-2,900,000$-1,746,000
    Income Tax Expense$70,000$58,000$20,000$4,000$21,000$12,000$-6,000$17,000$19,000$38,000$60,000$8,000
    Net Income$-1,266,000$-524,000$-184,000$-1,573,000$-994,000$-1,686,000$-834,000$-1,933,000$-2,679,000$-3,464,000$-2,960,000$-1,754,000
    EBITDA$-666,999$-94,000$2.07M$-1,203,000$-595,000$-1,293,000$-463,000$-1,641,000$-2,291,000$-3,023,000$-2,124,000$-1,391,000
    EBIT$-1,028,999$-466,000$1.65M$-1,569,000$-973,000$-1,674,000$-840,000$-1,916,000$-2,660,000$-3,426,000$-2,900,000$-1,746,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about IRIX

    Government Contracts

    Gov Obligations (TTM)
    $390861
    Gov Obligations / Revenue
    0.7%
    Obligations YoY
    N/A
    Active Awards
    17
    New Awards (TTM)
    16
    Avg Remaining Term
    2.0 mo

    Top agency: Department of Defense at 96.8% of trailing twelve month obligations across 2 agencies

    Recent Awards

    Award IDAgencyObligatedStart
    SPE2D425F734YDepartment of DefenseDefense Logistics Agency$117630Sep 23, 2025
    SPE2D425F739MDepartment of DefenseDefense Logistics Agency$94084Sep 24, 2025
    SPE2D426F6019Department of DefenseDefense Logistics Agency$73360Jan 22, 2026
    SPE2D426F152ZDepartment of DefenseDefense Logistics Agency$44194Apr 17, 2026
    SPE2D426F4056Department of DefenseDefense Logistics Agency$22272Dec 22, 2025
    SPE2D426F7245Department of DefenseDefense Logistics Agency$6870Feb 5, 2026
    SPE2D426F6219Department of DefenseDefense Logistics Agency$5568Jan 23, 2026
    SPE2D425F680MDepartment of DefenseDefense Logistics Agency$4207Sep 15, 2025
    SPE2D426F2731Department of DefenseDefense Logistics Agency$3341Dec 5, 2025
    SPE2D425F557FDepartment of DefenseDefense Logistics Agency$1114Aug 19, 2025

    Federal contract obligations are bookings recorded by the awarding agency, not recognized revenue. They can exceed 100% of revenue and can be negative when contracts are de-obligated. Source: USAspending.gov prime awards, data through Jul 31, 2026.

    News

    Retinal Detachment Market Outlook Signals Expansion To $3.14 Billion Through 2030

    The retinal detachment market is projected to expand significantly, reaching $3.14 billion by 2030 with a CAGR of 6.4%. This growth is driven by an aging global population, advancements in surgical technologies, increased ophthalmic research funding, and a focus on early intervention. Key players like Carl Zeiss Meditec AG are making strategic acquisitions to enhance their market presence and product portfolios, while emerging trends include minimally invasive procedures and specialized surgical retina services.

    openPR.com•8/26/26•
    Neutral

    IRIDEX (IRIX) CFO adds 6,668 shares in open-market buys

    IRIDEX CORP's CFO, Romeo R. Dizon, purchased a total of 6,668 shares of the company's Common Stock in open-market transactions on August 24, 2026. These purchases, made at prices around $0.75 per share, increased his direct ownership to 169,952 shares. This insider activity indicates a net buy of 6,668 shares, valued at approximately $5,000.

    Stock Titan•8/24/26•
    Bullish

    Analysts’ Opinions Are Mixed on These Healthcare Stocks: Iridex (IRIX) and Aurora Cannabis (ACB)

    Analysts have issued mixed ratings for healthcare stocks Iridex (IRIX) and Aurora Cannabis (ACB). Alliance Global Partners maintained a Buy rating for Iridex with a $2.75 price target, while ATB Cormark Capital Markets gave Aurora Cannabis a Hold rating with a C$5.60 price target. The article highlights both companies' recent stock performance and analyst consensus ratings.

    The Globe and Mail•8/21/26•
    Somewhat-Bullish

    Iridex: Q2 Earnings Snapshot

    Iridex Corp. (IRIX) reported a second-quarter loss of $1.3 million, or 7 cents per share, on revenue of $12.6 million. The medical laser company, based in Mountain View, California, projects full-year revenue to be between $51 million and $53 million. This information was generated by Automated Insights using data from Zacks Investment Research.

    Barchart.com•8/19/26•
    Somewhat-Bearish

    Iridex Reports Second Quarter 2026 Financial Results

    Iridex Corporation reported its financial results for the second quarter ended July 4, 2026, with total revenue of $12.6 million, a 7% decline year-over-year. The company saw strong growth in its Cyclo G6® glaucoma product family, with a 19% revenue increase, but this was offset by a weaker performance in retina product sales due to international disruptions. Iridex reaffirmed its annual revenue guidance for 2026 and plans to use working capital to increase inventory ahead of a headquarters relocation.

    GlobeNewswire•8/18/26•
    Somewhat-Bearish

    Frequently Asked Questions About IRIX

    Does IRIX pay dividends?
    IRIDEX Corporation (IRIX) does not currently pay a regular dividend.
    What is IRIX's market cap?
    IRIDEX Corporation (IRIX) has a market capitalization of $12.60M with a current stock price of $0.72.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In